FacebookTwitterGoogle+RedditEmail

Pfizer Too Big (and Slippery) to Fail

by

It’s only been a year since the Treasury Department drafted new proposals to stop Big Pharma from enacting brazen tax evasion or “tax inversions”– reincorporating in countries like Britain, Ireland or the Netherlands to duck US taxes, often merging with a European entity.

Before the new Treasury Department proposals, Illinois-based AbbVie sought to merge with ADHD drug maker Shire, based on a small island in the English Channel, in a deal that would have made it bigger than Boeing or McDonald’s. Illinois-based Walgreen, the US’s largest pharmacy chain, also sought a tax inversion but changed its mind when customers and lawmakers called the maneuver unpatriotic and unfair to corporations remaining in the US. Still, scandal-ridden device maker Medtronic succeeded in such a tax inversion, moving its headquarters to Ireland by acquiring Dublin-based Covidien PLC and reducing the tax it pays on profits earned overseas from 35 to 5 percent. Nice tax rate if you can get it.

While Pfizer’s original overture to acquire AstraZeneca for a tax inversion was rebuffed by the British drug giant, its recently announced proposed merger with Dublin-based Allergan is expected to go through because it gets around the new Treasury proposals. The shameless $160 billion deal between the makers of Lipitor and Viagra (Pfizer) and makers of Botox (Allergan) to dodge US taxes even as they live off high-priced drugs sold in the US, has drawn ire from both sides of the aisle- Hillary Clinton and Donald Trump.

Repeat Offender

To say Pfizer has been accused of wrongdoing in the past is like saying BP had an oil spill. Even as Pfizer was under a 5-year Corporate Integrity Agreement (CIA) with HHS for withholding $20 million in Lipitor rebates owed to Medicaid in 2002, it was marketing Neurontin for off-label indications which earned it a second CIA in 2004. And even as it entered into the second CIA, it was marketing Lyrica and other meds for off-label indications which earned it a third CIA! Does anyone notice that CIAs are…not a deterrent?

When it comes to corruption and scandals, Pfizer seems to court trouble. It bought Warner-Lambert in 2000 knowing the company’s marketing practices were under criminal investigation and its Rezulin had been withdrawn.  Then it bought hormone maker Wyeth knowing it had a thicket of Fen-Phen heart valve suits and Prempro cancer suits. Pfizer admits spying on medical students who were protesting against Big Pharma’s influence in medical education!

During one week in June of 2010,  Pfizer

1) agreed to pull its 10-year-old leukemia drug Mylotarg from the market because it caused more not less patient deaths

2) Suspended pediatric trials of Geodon two months after the FDA said children were being overdosed in the trials

3) Suspended trials of tanezumab, an osteoarthritis pain drug, because patients got worse not better, some needing joint replacements

4) Was investigated by the House for off-label marketing of the kidney transplant drug Rapamune and targeting African-Americans

5) Witnessed its client researcher, Scott S Reuben, MD, who put Bextra, Celebrex and Lyrica on the map, trotted off to prison for research fraud

6) was sued by Blue Cross Blue Shield to recoup money it overpaid for Bextra and other drugs

7) received a letter from Sen. Charles Grassley (R-Iowa) requesting its whistleblower policy and

8) had its appeal to end lawsuits by Nigerian families who accused it of illegal trials of the antibiotic Trovan in which 11 children died, rejected by the Supreme Court

Too Big To Fail

In the sentencing memo related to Pfizer’s third CIA, the Department of Justice wrote that  “illegal conduct was pervasive throughout the company and stemmed from messages created at high levels within the national marketing team.” Employees, it wrote “including district managers, explained that they did not question their supervisors about the illegal conduct that they were being instructed to carry out, because to do so would be considered a ‘CLM’ or ‘Career Limiting Move.’ 

Yet, when I asked industry analysts why the company is not shut down, blocked from tax supported programs like Medicare that enrich it and/or its officers tried and jailed,  Peter Rost, MD, author of The Whistleblower: Confessions of a Healthcare Hitman told me “So many Medicaid, Medicare and VA drugs come from Pfizer, the government would never convict them. It would stop the drug flow.”

Jim Edwards, former managing editor of Adweek, agreed. “Pfizer is the largest drug company in the world and if you include its generics unit it makes literally hundreds of different drugs. Getting tough would mean no Lipitor, no Viagra, no Bacitracin, no Cipro, no Zithromax, no Sutent, et cetera,” he told me. “The government is not really in a position to be cutting itself off from all that medicine.”

Pfizer is too big to fail or be regulated and so, apparently, is its tax dodge. But the tax evasion is not all bad news. Pfizer CEO Ian C. Read told lawmakers and administration officials this week that Pfizer’s lower tax bill will give it more cash to invest in the US and add jobs!

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

Weekend Edition
February 23, 2018
Friday - Sunday
Richard D. Wolff
Capitalism as Obstacle to Equality and Democracy: the US Story
Paul Street
Where’s the Beef Stroganoff? Eight Sacrilegious Reflections on Russiagate
Jeffrey St. Clair
They Came, They Saw, They Tweeted
Andrew Levine
Their Meddlers and Ours
Charles Pierson
Nuclear Nonproliferation, American Style
Joseph Essertier
Why Japan’s Ultranationalists Hate the Olympic Truce
W. T. Whitney
US and Allies Look to Military Intervention in Venezuela
John Laforge
Maybe All Threats of Mass Destruction are “Mentally Deranged”
Matthew Stevenson
Why Vietnam Still Matters: an American Reckoning
David Rosen
For Some Reason, Being White Still Matters
Robert Fantina
Nikki Haley: the U.S. Embarrassment at the United Nations
Joyce Nelson
Why Mueller’s Indictments Are Hugely Important
Joshua Frank
Pearl Jam, Will You Help Stop Sen. Tester From Destroying Montana’s Public Lands?
Dana E. Abizaid
The Attack on Historical Perspective
Conn Hallinan
Immigration and the Italian Elections
George Ochenski
The Great Danger of Anthropocentricity
Pete Dolack
China Can’t Save Capitalism from Environmental Destruction
Joseph Natoli
Broken Lives
Manuel García, Jr.
Why Did Russia Vote For Trump?
Geoff Dutton
One Regime to Rule Them All
Torkil Lauesen – Gabriel Kuhn
Radical Theory and Academia: a Thorny Relationship
Wilfred Burchett
Vietnam Will Win: The Work of Persuasion
Thomas Klikauer
Umberto Eco and Germany’s New Fascism
George Burchett
La Folie Des Grandeurs
Howard Lisnoff
Minister of War
Eileen Appelbaum
Why Trump’s Plan Won’t Solve the Problems of America’s Crumbling Infrastructure
Ramzy Baroud
More Than a Fight over Couscous: Why the Palestinian Narrative Must Be Embraced
Jill Richardson
Mass Shootings Shouldn’t Be the Only Time We Talk About Mental Illness
Jessicah Pierre
Racism is Killing African American Mothers
Steve Horn
Wyoming Now Third State to Propose ALEC Bill Cracking Down on Pipeline Protests
David Griscom
When ‘Fake News’ is Good For Business
Barton Kunstler
Brainwashed Nation
Griffin Bird
I’m an Eagle Scout and I Don’t Want Pipelines in My Wilderness
Edward Curtin
The Coming Wars to End All Wars
Missy Comley Beattie
Message To New Activists
Jonah Raskin
Literary Hubbub in Sonoma: Novel about Mrs. Jack London Roils the Faithful
Binoy Kampmark
Frontiersman of the Internet: John Perry Barlow
Chelli Stanley
The Mirrors of Palestine
James McEnteer
How Brexit Won World War Two
Ralph Nader
Absorbing the Irresistible Consumer Reports Magazine
Cesar Chelala
A Word I Shouldn’t Use
Louis Proyect
Marx at the Movies
Osha Neumann
A White Guy Watches “The Black Panther”
Stephen Cooper
Rebel Talk with Nattali Rize: the Interview
David Yearsley
Market Music
FacebookTwitterGoogle+RedditEmail